Catalyst Biosciences Publishes New Investor Presentation
01 août 2022 08h30 HE
|
Catalyst Biosciences, Inc.
Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an...
Catalyst Biosciences Announces Support from Largest Single Stockholder
01 août 2022 07h30 HE
|
Catalyst Biosciences, Inc.
JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst’s Nominees at the Company’s 2022 Annual Meeting Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the...
Catalyst Biosciences Sends Letter to Stockholders
19 juil. 2022 08h00 HE
|
Catalyst Biosciences, Inc.
Reiterates the Board’s Commitment to Expeditiously Distributing All of the Company’s Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior...
Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling
06 juil. 2022 08h00 HE
|
Catalyst Biosciences, Inc.
Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses Associated with Stockholder Litigation and...
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
29 juin 2022 08h00 HE
|
Catalyst Biosciences, Inc.
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set...
Catalyst Biosciences Sells Complement Portfolio for $60 Million
23 mai 2022 08h30 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex...
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
09 mai 2022 08h30 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31,...
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
31 mars 2022 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended...
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
15 mars 2022 17h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for...
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
17 févr. 2022 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to...